Please login to the form below
human growth hormone
This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.
NICE gives Lilly’s Verzenios chance to compete with rivals
Verzenios (abemaciclib) has been recommended in draft guidance by NICE in combination with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or ... This is for another
Latest news
-
FDA takes aim at pharma’s biosimilar-delaying tactics
Insulin action. Gottlieb is also planning to take action on high prices for insulin and other drugs such as human growth hormone which have seen their prices escalate in recent years.
-
CHMP recommends Teva's generic version of Astellas' Advagraf
The committee also recommended that Faslodex could be used in combination with Pfizer’s breast cancer drug Ibrance (palbociclib) to treat hormone receptor positive, human epidermal growth factor receptor 2-negative ... The combination can also be used
-
Lilly gets early US approval for Ibrance rival abemaciclib
The US FDA has approved the CDK 4/6 inhibitor - which will be sold as Verzenio - as a combination treatment with hormone drug fulvestrant for hormone receptor-positive, human epidermal growth
-
Versartis crashes as VELOCITY trial veers off track
The US biotech's somavaratan proved inferior to Pfzier’s Genotropin. US biotech Versartis saw more than 80% wiped off its share price ahead of the weekend after its growth hormone ... The long-acting human growth hormone (hGH) product had been billed
-
Surging Trulicity takes sting out of Lilly's arthritis setback
New chief executive David Ricks needs the drug and other growth brands to fire on all cylinders to help Lilly ride through the recent disappointment of a surprise FDA rejection for ... receptor-positive (HR+), human epidermal growth factor receptor
FDA takes aim at pharma’s biosimilar-delaying tactics
CHMP recommends Teva's generic version of Astellas' Advagraf
Lilly gets early US approval for Ibrance rival abemaciclib
Versartis crashes as VELOCITY trial veers off track
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Implementing eHealth innovation
Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which
-
Pharma deals during December 2014
costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth
Implementing eHealth innovation
Pharma deals during December 2014
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital strategist
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital project manager
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
No results were found
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
